ALT-B5, an optimized long-acting GHR antagonist with superior efficacy in models of acromegaly
June 11, 2024
Researchers from Alteogen Inc. and affiliated organizations presented preclinical characterization of a novel long-acting growth hormone receptor (GHR) antagonist, ALT-B5.
